effective at the close of trading on March 3, 2008.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
Forward Looking Statements -- This news release contains
forward-looking statements that involve significant risks and
uncertainties, including statements regarding Vermillion's plans,
objectives, expectations and intentions. These forward-looking statements
are based on Vermillion's current expectations. The Private Securities
Litigation Reform Act of 1995 provides a "safe harbor" for such
forward-looking statements. In order to comply with the terms of the safe
harbor, Vermillion notes that a variety of factors could cause actual
results and experience to differ materially from the anticipated results or
other expectations expressed in such forward-looking statements. There are
no guarantees that Vermillion will succeed in its efforts to commercialize
PAD, ovarian cancer or hematology diagnostics products in 2008 or during
any other period of time. Factors that could cause actual results to
materially differ include but are not limited to: (1) uncertainty in
obtaining intellectual property protection for inventions made by
Vermillion; (2) unproven ability of Vermillion to discover, develop, and
commercialize PAD, ovarian cancer or hematology diagnostic products based
on findings from its disease association studies; (3) unproven ability of
Vermillion to discover or identify
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved